$3.85
Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
Fulcrum and Slate Medicines sign merger agreement
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
Overview
52-week range
$2.83
$16
8% of range
Avg surprise (last 2)
+3.5%
Avg reaction (last 1)
+13.8%
100% positive
Latest IV / EM
435%
EM ±18.2% · $4 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.34 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $-0.25 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $-0.28 | $-0.29 | +3.5% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.28 | $-0.29 | +3.5% | — | +13.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.35 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.87 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.43 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.39 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.41 | — | — | — | — | financials |
| Fri Sep 30, 2022 | Sep 2022 | $-0.51 | — | — | — | — | financials |
| Thu Jun 30, 2022 | Jun 2022 | $-0.83 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-29M | $-22M | — | $-22M | — | $-20M | — | $-25M |
| Net income | $-26M | — | — | $-20M | — | — | — | $-22M |
| EPS (diluted) | $-0.34 | $-0.25 | — | $-0.31 | — | $-0.28 | — | $-0.35 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $48M | $50M | $198M | $47M | — | $42M | $58M | $73M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $323M | $339M | $357M | $206M | $219M | $233M | $250M | $267M |
| Total assets | $324M | $347M | $366M | $215M | $229M | $243M | $261M | $279M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $13M | $17M | $16M | $14M | $14M | $18M | $22M |
| Total equity | $311M | — | $349M | $198M | — | — | $243M | $257M |